Head and neck cancer
THE QUESTION A serious side effect of cancer radiotherapy is anemia, which produces fatigue. Does a drug that is sometimes prescribed to prevent or treat anemia affect a radiation patient’s cancer prognosis?
THIS STUDY compared disease progression in 214 patients with head and neck cancer who were randomly assigned to receive either a form of erythropoietin called epoetin beta (NeoRecormon) or placebo injections before and during radiotherapy. The researchers found that the placebo group had a 35 percent greater chance than the treatment group of living without further progression of their cancer for up to five years.
WHO MAY BE AFFECTED BY THESE FINDINGS? People with head and neck cancer who are receiving radiotherapy.
CAVEATS F. Hoffmann-La Roche, the manufacturer of NeoRecormon, funded the study. Also, the results may not apply to other formulations of erythropoietin or to other cancers.
BOTTOM LINE People receiving radiation may wish to consult their physician about the risks and benefits of epoetin beta.
FIND THIS STUDY Oct. 18 issue of The Lancet; abstract online at http://www.thelancet.com/journals/lancet/issue/current.
LEARN MORE ABOUT treating cancer-related anemia at www.asco.org and www.cancer.org.
This post has been viewed 2241 times.